Drug major Lupin Ltd today said it has entered into a licensing pact for various patents of cholesterol lowering drug 'Antara' capsules with US-based Abbott Laboratories and France's Laboratoires Fournier SA.
Lupin and its subsidiaries Lupin Pharmaceuticals Inc and Lupin Atlantis Holding SA, have entered into a licence agreement with Abbott Laboratories and Laboratoires Fournier SA for various Abbott patents for Antara (Fenofibrate) capsules, the company said in a statement.
The company did not disclose details of the patent licensing agreement citing confidentiality.
The agreement covers as many as eight patents in the US for the drug besides any divisionals, continuations, continuations in part, reissues, re-examinations, and extensions, it added.
Shares of Lupin today closed at Rs 419.20 on the Bombay Stock Exchange, up 1.09% from its previous close.